An observational study in Inflammatory Bowel Disease, Ulcerative Colitis and Crohn's Disease, sponsored by Kyungpook National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-16.
Sponsored by Kyungpook National University Hospital · Observational
The purpose of this study is to evaluate the development of anti-drug antibody to biosimilar CT-P13 and to assess the change of drug concentration for 1 year in patients with moderately to severe inflammatory bowel disease.
1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.
This study's enrollment of 280 is above the median of 162 across 608 observational studies indexed under Crohn Disease.
Browse Crohn Disease studies →Kyungpook National University Hospital is the lead sponsor of 76 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with moderate to severe inflammatory bowel disease who need to receive biosimilar CT-P13
Exclusion Criteria:
Patients with moderate to severe Crohn's disease who need to get a biosimilar CT-P13
Patients with moderate to severe ulcerative colitis who need to get a biosimilar CT-P13
Development of anti-drug antibody to CT-P13
Time frame: one year
Change of drug trough concentration
Time frame: one year
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kyungpook National University Hospital